Caribou Biosciences (CRBU) Return on Capital Employed (2021 - 2026)

Caribou Biosciences (CRBU) has 6 years of Return on Capital Employed data on file, last reported at 92.42% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 92.42%, down 3071.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 92.42% (down 3071.0% YoY), and the FY2025 annual result was 67.76%, down 1906.0% from the prior year.
• Return on Capital Employed steadied at 92.42% in Q1 2026 per CRBU's latest filing, from 92.85% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 18.16% in Q1 2022 and troughed at 92.85% in Q4 2025.
• A 5-year average of 48.03% and a median of 38.54% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2023 and 2025: Return on Capital Employed soared 185 bps in 2023, then sank 3766 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 29.71% in 2022, then rose by 6 bps to 27.86% in 2023, then sank by 101 bps to 55.88% in 2024, then slumped by 66 bps to 92.85% in 2025, then increased by 0 bps to 92.42% in 2026.
• Business Quant data shows CRBU's Return on Capital Employed at 92.42% in Q1 2026, 92.85% in Q4 2025, and 88.26% in Q3 2025.